Establishment Labs Holdings Inc. (ESTA)

Shares of Establishment Labs Holdings Inc. (NASDAQ: ESTA - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the eight research firms that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in the Jefferies 2025 London Healthcare Conference. Peter Caldini, Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, are scheduled to present in a fireside chat on Wednesday, November 19, 2025 at 8:30 a.m. GMT. A live webcast of the.

Establishment Labs Holdings Inc. ( ESTA ) Q3 2025 Earnings Call November 5, 2025 8:30 AM EST Company Participants Rajbir Denhoy - Chief Financial Officer Filippo Caldini - CEO & Director Conference Call Participants Anthony Petrone - Mizuho Americas LLC Joshua Jennings - TD Cowen, Research Division K. Gong - JPMorgan Chase & Co, Research Division Sam Eiber - BTIG, LLC, Research Division Mason Carrico - Stephens Inc., Research Division Michael Matson - Needham & Company, LLC, Research Division Presentation Operator Good afternoon.

Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to a loss of $0.59 per share a year ago.

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the third quarter ended September 30, 2025. Third Quarter Highlights and Outlook (Unaudited) Third quarter worldwide revenue of $53.8 million, an increase of 33.8% from the year ago period. Revenue included $11.9 million of Motiva sales in the.

Shares of Establishment Labs Holdings Inc. (NASDAQ: ESTA - Get Free Report) have earned an average recommendation of "Moderate Buy" from the seven ratings firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and five have given a buy

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended September 30, 2025, before the market opens on Wednesday, November 5, 2025, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S.

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, noted the publication of “The 3-Year Results of a 100-Patient Prospective Study of Safety and Effectiveness of Mia Femtech” in the Aesthetic Surgery Journal. The study showed a very low rate of complications, with no reports of capsular contracture (Baker Grade III/IV), implant rup.

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced publication of its 2025 Post-Market Surveillance (PMS) Report. The report is being released ahead of the annual meeting of the American Society of Plastic Surgeons held October 9-12 in New Orleans. “Publishing our PMS report every year since the launch of Motiva in 2010 s.

Establishment Labs Holdings Inc. (NASDAQ:ESTA ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Fillipo Peter Caldini - CEO & Director Rajbir Singh Denhoy - Chief Financial Officer Conference Call Participants Anthony Charles Petrone - Mizuho Americas LLC Joshua Thomas Jennings - TD Cowen, Research Division K. Gong - JPMorgan Chase & Co, Research Division Mason Owen Carrico - Stephens Inc., Research Division Matthew Charles Taylor - UBS Investment Bank, Research Division Mike Matson - Unidentified Company Sam Shimon Eiber - BTIG, LLC, Research Division Operator Good morning.

Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.54. This compares to a loss of $0.62 per share a year ago.

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the second quarter ended June 30, 2025. Second Quarter Highlights and Outlook (Unaudited) Second quarter worldwide revenue of $51.3 million, an increase of 16.3% from the year ago period. Revenue included $10.3 million of Motiva sales in the Un.

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended June 30, 2025, before the market opens on Thursday, August 7, 2025, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, dial (416) 764 8646 (U.S. and Ca.

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, will host its previously announced analyst and investor event in New York City on June 12, 2025 beginning at 1pm ET. A live and archived webcast of presentations and Q&A sessions on June 12 will be available on the "Investors" section of the Establishment Labs website at www.es.

NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in the Jefferies Global Healthcare Conference. Peter Caldini, Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, are scheduled to present in a fireside chat on Wednesday, June 4, 2025 at 7:35 a.m. ET. A live webcast of the presentati.

Establishment Labs Holdings, Inc. (NASDAQ:ESTA ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Peter Caldini - Chief Executive Officer Rajbir Denhoy - Chief Financial Officer Juan Jose Chacon-Quiros - Former CEO & Founder Conference Call Participants Marie Thibault - BTIG Joshua Jennings - TD Cowen Michael Matson - Needham & Company Allen Gong - JPMorgan Mason Carrico - Stephens Joanne Wuensch - Citibank Matthew Taylor - Jefferies Anthony Petrone - Mizuho Group Operator Good afternoon, and welcome to the Establishment Labs First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only mode.